Nestle Completes Acquisition Of Aimmune Therapeutics – Quick Facts

(RTTNews) – Nestle SA (NSRGY.PK, NSTR.L) announced the completion of its acquisition of Aimmune Therapeutics, Inc. (AIMT). Andrew Oxtoby has been named as Aimmune’s President & CEO. He was previously Aimmune’s Chief Commercial Officer.

The tender offer for all of the outstanding shares of Aimmune common stock, other than shares held by Nestlé and its affiliates, for a price of $34.50 per share in cash expired on October 9, 2020. The minimum tender condition and all of the other conditions to the offer were satisfied and on October 13. Nestlé through a subsidiary, accepted for payment all shares validly tendered and not properly withdrawn. Aimmune stock has ceased to be traded on the NASDAQ Global Market.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Source Article